Aurinia's Lupus Candidate Succeeds In Pivotal Study, Stock Up
Zacks Investment Research | Dec 04, 2019 08:51PM ET
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced that its pipeline candidate, voclosporin, met the primary endpoint in a pivotal phase III AURORA study evaluating it in patients with lupus nephritis ("LN"), an inflammation of the kidney caused by systemic lupus erythematosus. Data showed that the candidate achieved statistically significant improvements in clinically meaningful endpoints with a comparable safety profile to the current standard of care.
Based on the encouraging data from the study, the company is planning to file a new drug application to the FDA in the first half of 2020. It anticipates to commercially launch the candidate in early 2021.
Shares of Aurinia surged almost 120% in after-hours trading on Dec 4, following the data readout. The company’s shares have gained 23% so far this year compared with the industry ’s increase of 10.6%.
The AURORA study evaluated immunosuppressant candidate, voclosporin, for increase in speed of and overall renal response rates in patients with LN when added to background therapy of mycophenolate mofetil, another immunosuppressant, and low-dose corticosteroids. Data showed that patients receiving voclosporin achieved 40.8% renal response rate compared to 22.5% for the standard of care following a treatment period of 52 weeks. The candidate also achieved improvement of statistical significance in all pre-specified hierarchical secondary endpoints. The candidate was also well tolerated in patients.
The company believes the data from the pivotal study demonstrates that voclosporin can be a potential game changer for LN patients. It also believes that the candidate is the first novel treatment that has demonstrated therapeutic efficacy and no excess adverse events compared to standard of care.
Meanwhile, the company is evaluating the candidate in AURORA 2 extension study in patients who have completed the AURORA study for a duration of 104 weeks to assess the long-term benefit/risk of voclosporin in LN patients. The company mentioned in its press release that data from the study should be valuable in a post-marketing setting and for future interactions with various regulatory authorities.
Apart from the LN indication, Aurinia is also developing voclosporin across multiple inflammatory and autoimmune conditions.
We note that there are several big pharma companies that are also developing treatments for lupus. Biogen’s (NASDAQ:BIIB) lupus candidate, BIIB059, met the primary endpoint in a phase II study earlier this month. A phase II study is evaluating Roche’s (OTC:RHHBY) Gazyva as a treatment for LN patients. In August, AstraZeneca (NYSE:AZN) announced that anifrolumab met the primary endpoint of the phase III study evaluating it in lupus patients. We expect voclosporin to face competition from these drugs, upon their potential approval.
Get The News You Want
Aurinia Pharmaceuticals Inc Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.